Treatment with talazoparib (Talzenna) did not demonstrate a statistically significant overall survival (OS) benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer, according to updated findings from the phase 3 EMBRACA trial (NCT01945775).1 However, lead author Jennifer Litton, MD, said that there is still reason to believe treatment with the PARP inhibitor can improve OS.
The FDA has granted a breakthrough therapy designation to mobocertinib for the treatment of patients with EGFR exon 20–mutant non–small cell lung cancer.
While keeping patients at home decreases their risk of contracting the virus, it can also create challenges and safety issues when it comes to procedures like infusions.
Olaparib significantly improved overall survival versus abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer and BRCA1/2 or ATM mutations.
Containment strategies for patients at greatest risk of developing severe complications from COVID-19 are evolving, says Allyson Ocean, MD.
Cancer care may never be the same again after the COVID-19 pandemic. In a recent webinar, 2 oncology nurses discussed their experiences.
Combined treatment with brentuximab vedotin and nivolumab could provide a more tolerable option for older patients with classical Hodgkin lymphoma.
CAR T-cell therapy is poised to have a significant impact on the treatment of patients with relapsed/refractory multiple myeloma, says Nina Shah, MD.
The FDA has granted an accelerated approval to sacituzumab govitecan-hziy for the treatment of adult patients with pretreated metastatic triple-negative breast cancer.
The worldwide pandemic caused more healthcare providers to be out of work, as well as changes in patients’ treatment regimens.
The FDA approved ibrutinib (Imbruvica) plus rituximab (Rituxan) as a frontline therapy for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
A New Drug Application (NDA) has been submitted to the FDA for single-agent relugolix for use as a treatment for men with advanced prostate cancer, according to Myovant Sciences, the developer of the oral GnRH receptor antagonist.
The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib (Pemazyre), which the agency recently approved for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.
In light of the COVID-19 pandemic, transplant-eligible patients with cancer are undergoing careful assessment to determine whether they should proceed with the procedure or receive additional consolidation therapy to buy time, according to Naval G. Daver, MD.
While many providers are in favor of physician-assisted dying, others are against it, and payment may also become a barrier.
Just as the situation with COVID-19 continues to rapidly evolve, the oncology community must actively adapt how they approach the treatment of their patients based on the information available, according to Balazs Halmos, MD, MS.
Patients at risk of developing thrombosis should receive anticoagulants, in the form of Xa inhibitors and, if necessary, andexanet alfa (Andexxa) or prothrombin concentrates to control excessive bleeding, explained Alvin H. Schmaier, MD.
This is the first FDA approval for this patient population.
The FDA has approved tucatinib (Tukysa) for use in combination with trastuzumab (Herceptin) and capecitabine (Xeloda) for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 1 prior therapy.
Although the emergence of more targeted and immunotherapies continues to expand the melanoma treatment paradigm, surgery remains an important tool in the management of these patients, according to Omid Hamid, MD.
The COVID-19 pandemic has shocked the US healthcare system, highlighting our flaws while showing our deep commitment to quality patient care. We in healthcare cannot “pause,” but I am hoping millions of people around the world will do so and realign their convictions from the lessons learned.
Findings from the phase II FIGHT-202 study of pemigatinib in patients with previously treated, locally advanced or metastatic FGFR2-positive cholangiocarcinoma have been published in the Lancet Oncology as the FDA considers a new-drug application (NDA) for the treatment in this setting.
The FDA approved mitomycin gel (Jelmyto) for the treatment of patients with low-grade upper tract urothelial cancer (UTUC), cancer of the lining of the urinary system. This is the first therapy approved in this space.
Leading oncology and breast cancer organizations came together to create treatment recommendations for patients with breast cancer during the COVID-19 pandemic.
Acalabrutinib (Calquence), a BTK inhibitor approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), is being explored in the CALAVI trial as a treatment for cytokine storm in patients with COVID-19.
The relationship between the two maladies still remains vastly unknown.
The FDA granted priority review to the new drug application for sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to
T-cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) therapy, and CAR T-cell therapy, which have shown preliminary signals of activity, are poised to have a dramatic impact in metastatic melanoma, according to Jason J. Luke, MD, FACP.
We want to hear from you what you think about telemedicine and in-home cancer care during the COVID-19 pandemic.
An increased proportion of Indigenous American (IA) genetic ancestry may be linked with a higher incidence of HER2-positive breast cancer, according to findings from a study published in Cancer Research.
